Surface Ophthalmics Raises $25M in Funding
- Surface Ophthalmics, a Pleasanton CA-based pharmaceutical company, raised $25M in funding
- Investors included both new and existing investors made up of institutional, healthcare-focused, and other accredited investors
- The company intends to use the funds to advance its clinical programs in ocular diseases
- The company is a pharmaceutical company focused on the development and commercialization of innovative therapeutics for ocular diseases
- The company will be positioned to begin enrolling patients in Phase III clinical trials, targeting FDA approval
- These programs utilize Klarity® as the delivery vehicle, which is designed to enhance patient comfort as well as protect and rehabilitate the ocular surface
